IMNM Immunome Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: IMNM

Price (delayed)

$15.75

Market cap

$940.18M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$5.38

Enterprise value

$841.41M

Immunome is a biopharmaceutical company that utilizes its proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics that are designed to change the way diseases are ...

Highlights
Immunome's quick ratio has surged by 127% YoY and by 61% QoQ
Immunome's gross profit has increased by 38% QoQ
IMNM's EPS has shrunk by 197% QoQ and by 74% YoY
IMNM's net income has dropped by 189% year-on-year
Sector: Healthcare
Industry: Biotechnology
Website: http://immunome.com
Peers: OMER OMGA

Key stats

What are the main financial stats of IMNM
Market
Shares outstanding
59.69M
Market cap
$940.18M
Enterprise value
$841.41M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
5.61
Price to sales (P/S)
22.3
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
60.02
Earnings
Revenue
$14.02M
EBIT
-$106.81M
EBITDA
-$106.08M
Free cash flow
-$8.4M
Per share
EPS
-$5.38
Free cash flow per share
-$0.42
Book value per share
$2.81
Revenue per share
$0.71
TBVPS
$7.49
Balance sheet
Total assets
$148.54M
Total liabilities
$28.66M
Debt
$0
Equity
$119.88M
Working capital
$122.87M
Liquidity
Debt to equity
0
Current ratio
6.63
Quick ratio
6.33
Net debt/EBITDA
0.93
Margins
EBITDA margin
-756.7%
Gross margin
100%
Net margin
-761.9%
Operating margin
-781.4%
Efficiency
Return on assets
-129%
Return on equity
-286.4%
Return on invested capital
N/A
Return on capital employed
-84.3%
Return on sales
-761.9%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

IMNM stock price

How has the Immunome stock price performed over time
Intraday
5.21%
1 week
14.71%
1 month
-27.08%
1 year
209.43%
YTD
47.2%
QTD
-36.18%

Financial performance

How have Immunome's revenue and profit performed over time
Revenue
$14.02M
Gross profit
$14.02M
Operating income
-$109.53M
Net income
-$106.81M
Gross margin
100%
Net margin
-761.9%
Immunome's operating income has shrunk by 197% YoY
IMNM's net income has dropped by 189% year-on-year
Immunome's gross profit has increased by 38% QoQ
The revenue rose by 38% QoQ

Growth

What is Immunome's growth rate over time

Valuation

What is Immunome stock price valuation
P/E
N/A
P/B
5.61
P/S
22.3
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
60.02
IMNM's EPS has shrunk by 197% QoQ and by 74% YoY
The price to book (P/B) is 36% lower than the last 4 quarters average of 8.8
The revenue rose by 38% QoQ
IMNM's price to sales (P/S) is 36% higher than its last 4 quarters average of 16.4

Efficiency

How efficient is Immunome business performance
Immunome's ROE has plunged by 106% YoY and by 50% from the previous quarter
The company's return on assets fell by 21% YoY

Dividends

What is IMNM's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for IMNM.

Financial health

How did Immunome financials performed over time
Immunome's quick ratio has surged by 127% YoY and by 61% QoQ
The current ratio has soared by 115% YoY and by 67% QoQ
IMNM's debt is 100% smaller than its equity

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.